Biology of metabolic syndrome in a vascular patient

Vascular

Volumn 20, Issue 3, 2012, Pages 156-163

  Vykoukal, Daynene ^a   Davies, Mark G ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Adipokines; Insulin resistance; Metabolic syndrome; Obesity; Vascular biology

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; FATTY ACID; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; BODY MASS; BRAIN BLOOD VESSEL; CARDIOVASCULAR RISK; CORONARY BLOOD VESSEL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIMB DISEASE; LIPID STORAGE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM; WAIST CIRCUMFERENCE; WEIGHT GAIN;

DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; VASCULAR DISEASES;

EID: 84864131834     PISSN: 17085381     EISSN: 1708539X     Source Type: Journal    
DOI: 10.1258/vasc.2011.201201     Document Type: Review

References (115)

1. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-607 (Pubitemid 19004941)
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52 (Pubitemid 41532612)
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53 (Pubitemid 28319935)
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28 (Pubitemid 40523737)
5. Gorter PM, Olijhoek JK, van der Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004;173:363-9 (Pubitemid 38469808)
6. Brevetti G, Schiano V, Sirico G, Giugliano G, Laurenzano E, Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 2006;44:101-7 (Pubitemid 43975268)
7. Vlek AL, van der Graaf Y, Sluman MA, Moll FL, Visseren FL, SMART Study Group. Metabolic syndrome and vascular risk in patients with peripheral arterial occlusive disease. J Vasc Surg 2009;50:61-9
8. Olijhoek JK, van der Graaf Y, Banga JD, et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004;25:342-8 (Pubitemid 38295444)
9. Mori T, Ohashi Y, Ejiri J, Takatsuki K, Ichikawa S, Awano K. Impact of metabolic syndrome and diabetes mellitus on cardiovascular events in coronary artery disease without ischemia on stress thallium-201 single photon emission computed tomography after percutaneous coronary intervention. J Cardiol 2005;46:89-96 (Pubitemid 41441931)
10. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 2006;7:7 -11
11. Chung EH, Curran PJ, Sivasankaran S, et al. Prevalence of metabolic syndrome in patients ≤45 years of age with acute myocardial infarction having percutaneous coronary intervention. Am J Cardiol 2007; 100:1052-5 (Pubitemid 47404459)
12. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8 (Pubitemid 38063699)
13. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808 (Pubitemid 38063703)
14. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305-13 (Pubitemid 41134256)
15. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008;100:227-35
16. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007;56:901-11 (Pubitemid 46525054)
17. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007;455:479 -92
18. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome - an allostatic perspective. Biochim Biophys Acta 2010;180:338-49
19. Johnson ON 3rd, Sidawy AN, Scanlon JM, et al. Impact of obesity on outcomes after open surgical and endovascular abdominal aortic aneurysm repair. J Am Coll Surg 2010;210:166-77
20. Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J Vasc Surg 2009; 49:140-47
21. Giles KA, Hamdan AD, Pomposelli FB, Wyers MC, Siracuse JJ, Schermerhorn ML. Body mass index: surgical site infections and mortality after lower extremity bypass from the National Surgical Quality Improvement Program 2005-2007. Ann Vasc Surg 2010;24:48-56
22. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-46
23. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007; 56:728-34 (Pubitemid 46348477)
24. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 2007;30:591-6 (Pubitemid 46354339)
25. Palomo I, Alarcón M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome. Int J Mol Med 2006;18:969-74
26. Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta 2010;180:327-37
27. Assimacopoulos-Jeannet F. Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes. Int J Obes Relat Metab Disord 2004;28(Suppl 4):S53-7 (Pubitemid 40143849)
28. Karastergioua K, Mohamed-Alia V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010;318:69-78
29. Matsuda M, Shimomura I. Adipocytokines and metabolic syndrome - molecular mechanism and clinical implication. Nippon Rinsho 2004;62:1085-90
30. Hillenbrand A, Weiss M, Knippschild U, et al. Association of adiponectin levels and insulin demand in critically ill patients. Diabetes Metab Syndr Obes 2011; 26:45-51
31. Rahmouni K, Correia MLG, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005;45:9-14 (Pubitemid 40066405)
32. Lastra G, Manrique C, Sowers JR. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis 2006;13:365-73 (Pubitemid 44512240)
33. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006;26:232-44 (Pubitemid 44114394)
34. Corpeleijn E, Bakker SJ, Stolk RP. Obesity and impaired renal function: potential for lifestyle intervention? Eur J Epidemiol 2009;24:275-80
35. Kramer H, Luke A. Obesity and kidney disease: a big dilemma. Curr Opin Nephrol Hypertens 2007;16:237-41 (Pubitemid 46608531)
36. Wei YD, Hu DY, Zhang RF, et al. Metabolic syndrome complicated by peripheral arterial disease: clinical study of 2115 cases. Zhonghua Yi Xue Za Zhi 2006;86:2114-6
37. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008;17:450-6
38. Davies MG, Bismuth J, Saad WE, Naoum JJ, Peden EK, Lumsden AB. Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting. J Vasc Surg 2010;51:926-32
39. Brownlee M, Cerami A, Vlassara H. Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1988;4:437- 51
40. Getz GS. Report on the workshop on diabetes and mechanisms of atherogenesis. Arterioscler Thromb 1993;13:459-64
41. Agrawal DK, Bhimji S, McNeill JH. Effect of chronic experimental diabetes on vascular smooth muscle function in rabbit carotid artery. J Cardiovasc Pharmacol 1987;9:584-93 (Pubitemid 17069876)
42. MacLeod KM, McNeill JH. The influence of chronic experimental diabetes on contractile responses of rat isolated blood vessels. Can J Physiol Pharmacol 1985;63:52-7 (Pubitemid 15148317)
43. Koschinsky T, Bunting CE, Rutter R, Gries FAS. Vascular growth factors and the development of macrovascular disease in diabetes mellitus. Diab Metabol 1987;13:318-25 (Pubitemid 17105092)
44. Fuster V. Progression-regression of atherosclerosis: molecular, cellular and clinical bases. Circulation 1992;86 (Suppl III):1-123
45. Zhang F, Kent KC, Yamanouchi D, et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009;250: 416 -23
46. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426-32 (Pubitemid 32954818)
47. Paciaroni M, Agnellim G, Caso V, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis 2009;28:119-23
48. Hsu SS, Meno JR, Zhou JG, Gordon EL, Winn HR. Influence of hyperglycemia on cerebral adenosine production during ischemia and reperfusion. Am J Physiol 1991;261:H398-403
49. Ishihara M, Inoue I, Kawagoe T, et al. Effect of acute hyperglycemia on the ischemic preconditioning effect of prodromal angina pectoris in patients with a first anterior wall acute myocardial infarction. Am J Cardiol 2003; 92:288 -91
50. Kawai N, Keep RF, Betz AL, Nagao S. Hyperglycemia induces progressive changes in the cerebral microvasculature and blood-brain barrier transport during focal cerebral ischemia. Acta Neurochir 1998;(Suppl)71:219-21 (Pubitemid 128444402)
51. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003;34:2208-14 (Pubitemid 37099838)
52. Kinoshita K, Kraydieh S, Alonso O, Hayashi N, Dietrich WD. Effect of posttraumatic hyperglycemia on contusion volume and neutrophil accumulation after moderate fluid-percussion brain injury in rats. J Neurotrauma 2002;19:681-92 (Pubitemid 34761332)
53. Protack CD, Bakken AM, Xu J, Saad WE, Lumsden AB, Davies MG. Metabolic syndrome: a predictor of adverse events after carotid revascularization. J Vasc Surg 2009;49:1172-80
54. McGirt MJ, Woodworth GF, Brooke BS, et al. Hyperglycemia independently increases the risk of perioperative stroke, myocardial infarction, and death after carotid endarterectomy. Neurosurgery 2006 58:1066-73
55. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8 (Pubitemid 30128815)
56. Gasior M, Stasik-Pres G, Pres D, et al. Relationship between blood glucose on admission and prognosis in patients with acute myocardial infarction treated with percutaneous coronary intervention. Kardiol Pol 2007;65:1031-8 (Pubitemid 350096908)
57. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007;12:2957-66
58. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009;10:554-63
59. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002;106:2442-7 (Pubitemid 35278799)
60. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhanvague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7 (Pubitemid 27188265)
61. Cigolini M, Tonoli M, Borgato L, et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-&alpha? Atherosclerosis 1999;143:81 -90
62. Alessi MC, Bastelica D, Morange P, Berthet BIL, Verdier M, et al. Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49:1374-80 (Pubitemid 30624239)
63. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006;30:1308-14 (Pubitemid 44141622)
64. Kanaya AM, Wassel FC, Vittinghoff E, et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006;166:350-6 (Pubitemid 43244324)
65. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7 (Pubitemid 17022002)
66. Song CZ, Siok TE, Gelehrter TD. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 1998;273:29287-90 (Pubitemid 28509925)
67. Varma V, Yao-Borengasser A, Bodles AM, et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008;57:432-9
68. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001;107:929-34 (Pubitemid 32323400)
69. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004;122:135-42 (Pubitemid 39441244)
70. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell Metab 1998;93:1159-70 (Pubitemid 28307421)
71. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996;93:106-10 (Pubitemid 26006576)
72. Steffen LM, Cushman M, Peacock JM, et al. Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost 2009;7:746-51
73. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006;4:1914-8 (Pubitemid 44226768)
74. Ray JG, Lonn E, Yi Q, et al. Venous thromboembolism in association with features of the metabolic syndrome. QJM 2007;100:679-84 (Pubitemid 350042428)
75. Dentali F, Ageno W, Romualdi E, Pesavento R, Ghirarduzzi A, Prandoni P. Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study. Haematologica 2007;92:1293-4 (Pubitemid 350144203)
76. Gnacińska M, Małgorzewicz S, Lysiak-Szydłowska W, Sworczak K. The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol Pol 2010;61:36-41
77. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745-E51
78. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005;54:2939-45 (Pubitemid 41401090)
79. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389:610-4 (Pubitemid 27446179)
80. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-α-mediated insulin resistance in genetic obesity. Endocrinology 1998;139:4832-8 (Pubitemid 28533428)
81. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5 (Pubitemid 26225502)
82. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6
83. Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-α treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol 2008;35:355-7 (Pubitemid 351281162)
84. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8 (Pubitemid 47201685)
85. Andreozzi F, Laratta E, Procopio C, et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007; 27:2372-83 (Pubitemid 46418488)
86. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-7 (Pubitemid 36323590)
87. van Exel E, Gussekloo J, Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-plus study. Diabetes 2002;51:1088-92 (Pubitemid 34438354)
88. Straczkowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M. Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care 2005; 28:2036-7 (Pubitemid 41060983)
89. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804 (Pubitemid 37430249)
90. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305-13 (Pubitemid 41134256)
91. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100:7265-70 (Pubitemid 36706427)
92. Marso SP, Murphy JW, House JA, Safley DM, Harris WS. Metabolic syndrome-mediated inflammation following elective percutaneous coronary intervention. Diab Vasc Dis Res 2005; 2:31-6 (Pubitemid 40333202)
93. Dohi T, Miyauchi K, Kasai T, et al. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009;73:1454-8
94. Nikolsky E, Kosinski E, Mishkel GJ, et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 2005;95:709-15 (Pubitemid 40332647)
95. Sarno G, Garg S, Onuma Y, et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). Am J Cardiol 2010;105:475-9
96. Ndrepepa G, Keta D, Byrne RA, et al. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. Heart Vessels 2010;25:27-34
97. Tartan Z, Ozer N, Uyarel H, et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. Nutr Metab Cardiovasc Dis. 2008;18:441-7 (Pubitemid 351902252)
98. Canibus P, Faloia E, Piva T, et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism 2008;57:593-7 (Pubitemid 351608218)
99. Stellbrink E, Schröder J, Grawe A, et al. Impact of metabolic syndrome on clinical and angiographic outcome after sirolimus-eluting stent implantation. Coron Artery Dis 2007;18:601-6
100. Rana JS, Monraats PS, Zwinderman AH, et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 2005;28:873-7 (Pubitemid 40434488)
101. Wallenfeldt K, Hulthe J, Fagerberg B. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intl Med 2005;258:28-37 (Pubitemid 40904930)
102. Iannuzzi A, De Michele M, Bond MG, et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the 'Progetto ATENA' Study). Am J Cardiol 2005;96:1162-5 (Pubitemid 41416614)
103. Scuteri A, Najjar SS, Muller DC, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004;43:1388 -95
104. Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM. Hemostasis alterations in metabolic syndrome. Int J Mol Med 2006;18:969-74
105. Bonora E, Egger G, Kiechl S, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. Diabetes Care 2003;26:1251-7
106. Koren-Morage N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366-71 (Pubitemid 40967495)
107. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(11 suppl):I213-9 (Pubitemid 47480793)
108. Winter Y, Rohrmann S, Linseisen J, et al. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke 2008;39:145-51
109. Zhang CE, van Raak EP, Rouhl RP, et al. Metabolic syndrome relates to lacunar stroke without white matter lesions: a study in first-ever lacunar stroke patients. Cerebrovasc Dis 2010;29: 503-7
110. Kasai T, Miyauchi K, Kajimoto K, et al. Relationship between the metabolic syndrome and the incidence of stroke after complete coronary revascularization over a 10-year follow-up period. Atherosclerosis 2009;207:195-9
111. Kasai T, Miyauchi K, Kajimoto K, et al. The adverse prognostic significance of the metabolic syndrome with and without hypertension in patients who underwent complete coronary revascularization. J Hypertens 2009;27:1017-24
112. Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer 's disease. Ageing Res Rev 2010;9:399-417
113. van Kuijk JP, Flu WJ, Chonchol M, Bax JJ, Verhagen HJ, Poldermans D. Metabolic syndrome is an independent predictor of cardiovascular events in high-risk patients with occlusive and aneurysmatic peripheral arterial disease. Atherosclerosis 2010;2:596-601
114. Brevetti G, Laurenzano E, Giugliano G, et al. Metabolic syndrome and cardiovascular risk prediction in peripheral arterial disease. Nutr Metab Cardiovasc Dis 2009;20:676-82
115. Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation 2009; 120:1041-7